A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation

Creative Commons License

Cremers E. M. P., de Witte T., de Wreede L., Eikema D., Koster L., van Biezen A., ...Daha Fazla

LEUKEMIA & LYMPHOMA, cilt.60, sa.10, ss.2404-2414, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 60 Sayı: 10
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1080/10428194.2019.1594215
  • Dergi Adı: LEUKEMIA & LYMPHOMA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.2404-2414
  • Anahtar Kelimeler: MDS, allogeneic stem cell transplantation, transfusions, phlebotomies, chelation therapy, PROGNOSTIC SCORING SYSTEM, ACUTE MYELOID-LEUKEMIA, TRANSFERRIN-BOUND IRON, C-REACTIVE PROTEIN, SERUM FERRITIN, OVERLOAD, MDS, BLOOD, INTENSITY, SURVIVAL
  • Gazi Üniversitesi Adresli: Evet

Özet

Most myelodysplastic syndromes (MDS)-patients receive multiple red blood cell transfusions (RBCT). Transfusions may cause iron-related toxicity and mortality, influencing outcome after allogeneic HSCT. This prospective non-interventional study evaluated 222 MDS and CMML patients undergoing HSCT. Overall survival (OS), relapse-free survival (RFS), non-relapse mortality (NRM), and relapse incidence (RI) at 36 months were 52%, 44%, 25%, and 31%, respectively. Age, percentage of marrow blasts and severe comorbidities impacted OS. RFS was significantly associated with RBCT burden prior to HSCT (HR: 1.7; p = .02). High ferritin levels had a significant negative impact on OS and RI, but no impact on NRM. Administration of iron chelation therapy prior to HSCT did not influence the outcome, but early iron reduction after HSCT (started before 6 months) improved RFS significantly after transplantation (56% in the control group vs. 90% in the treated group, respectively; p = .04). This study illustrates the impact of RBCT and related parameters on HSCT-outcome. Patients with an expected prolonged survival after transplantation may benefit from early iron reduction therapy after transplantation.